(PDF) In Vitro and in Vivo Characterization of Irreversible

In Vitro and in Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing

Molecular Cancer Therapeutics - United States

doi 10.1158/1535-7163.mct-13-0966

Full Text

Open PDF

Abstract

Available in full text

Date

April 10, 2014

Authors

Publisher

American Association for Cancer Research (AACR)

Related search

Structural Differences Between Wild-Type and Double Mutant EGFR Modulated by Third-Generation Kinase Inhibitors

Journal of the American Chemical Society

English

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

Clinical Cancer Research

Cancer Research

Oncology

2015

English

Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models With EGFR Activating Mutations, T790M Mutation and AXL Overexpression

Molecular Cancer Therapeutics

Cancer Research

Oncology

2019

English

Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors

Cancer Research

Oncology

2017

English

New Heteroaryl Carbamates: Synthesis and Biological Screening in Vitro and in Mammalian Cells of Wild-Type and Mutant HIV-protease Inhibitors

Bioorganic and Medicinal Chemistry

Clinical Biochemistry

Pharmaceutical Science

Drug Discovery

2019

English

Selective Inhibitors of the Osteoblast Proteasome Stimulate Bone Formation in Vivo and in Vitro

Journal of Clinical Investigation

Medicine

2003

English

Biochemical Characterization of Arabidopsis Wild-Type and Mutant Phytochrome B Holoproteins

English

YH25448, an Irreversible EGFR-TKI With Potent Intracranial Activity in EGFR Mutant Non-Small-Cell Lung Cancer

Clinical Cancer Research

Cancer Research

Oncology

2019

English

Structure-Based Design of 5Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S)

English

Amanote Research

In Vitro and in Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing

Molecular Cancer Therapeutics - United States

doi 10.1158/1535-7163.mct-13-0966

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Structural Differences Between Wild-Type and Double Mutant EGFR Modulated by Third-Generation Kinase Inhibitors

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models With EGFR Activating Mutations, T790M Mutation and AXL Overexpression

Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors

New Heteroaryl Carbamates: Synthesis and Biological Screening in Vitro and in Mammalian Cells of Wild-Type and Mutant HIV-protease Inhibitors

Selective Inhibitors of the Osteoblast Proteasome Stimulate Bone Formation in Vivo and in Vitro

Biochemical Characterization of Arabidopsis Wild-Type and Mutant Phytochrome B Holoproteins

YH25448, an Irreversible EGFR-TKI With Potent Intracranial Activity in EGFR Mutant Non-Small-Cell Lung Cancer

Structure-Based Design of 5Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S)